Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03781726 · ClinicalTrials.gov registry record · Phase 4
Multi-center Study to Transplant Hepatitis-C Infected Kidneys
A Phase 4 study, sponsored by Raymond Chung.
- Completed
- Registry status
- Phase 4
- Development phase
- 30
- Enrollment target
NCT03781726 is a Phase 4 study that has completed, run by Raymond Chung. The registered enrollment target is 30 participants.
The verdict
NCT03781726, a Phase 4 study, has completed, sponsored by Raymond Chung.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 30 participants
- Enrollment target
Study Summary
Open label multi center study for the donation of HCV positive kidneys to HCV negative recipients with interventional treatment to prevent HCV transmission upon transplantation.
Interventions
- DRUG glecaprevir/pibrentasvir treatment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2019-04-10 |
| Est. Completion | 2021-12-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03781726
The ClinicalTrials.gov registry entry for NCT03781726 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Raymond Chung, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which glecaprevir/pibrentasvir treatment is the first listed.
NCT03781726 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03781726 about?
NCT03781726 is a clinical study titled "Multi-center Study to Transplant Hepatitis-C Infected Kidneys". Open label multi center study for the donation of HCV positive kidneys to HCV negative recipients with interventional treatment to prevent HCV transmission upon transplantation.
What is the current status of trial NCT03781726?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2019-04-10. Estimated completion is 2021-12-31.
What interventions are being tested in trial NCT03781726?
The interventions under investigation include: glecaprevir/pibrentasvir treatment (DRUG).
Who is sponsoring clinical trial NCT03781726?
This trial is sponsored by Raymond Chung, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.